Patents by Inventor Michael Serrano-Wu

Michael Serrano-Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for treating or inhibiting recurrence of acute myeloid leukemia
    Patent number: 11963960
    Abstract: This invention relates to compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: April 23, 2024
    Assignee: Flash Therapeutics, LLC
    Inventors: Michael Serrano-Wu, Zhixiong Ye, Kejia Ding
  • COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA
    Publication number: 20210299128
    Abstract: This invention relates to compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 30, 2021
    Inventors: Michael Serrano-Wu, Zhixiong Ye, Kejia Ding
  • Substituted aminothiazoles for the treatment of tuberculosis
    Patent number: 10221169
    Abstract: Disclosed ore substituted aminothiazoles, which can be used for, among other things, the treatment of tuberculosis, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 5, 2019
    Assignees: The Broad Institute, Inc., The General Hospital Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Deborah Hung, Michael Serrano-Wu, Sarah Grant, Tomohiko Kawate
  • SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS
    Publication number: 20170305895
    Abstract: Disclosed ore substituted aminothiazoles, which can be used for, among other things, the treatment of tuberculosis, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Application
    Filed: March 23, 2017
    Publication date: October 26, 2017
    Inventors: Deborah Hung, Michael Serrano-Wu, Sarah Grant, Tomohiko Kawate
  • 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
    Patent number: 9676728
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: June 13, 2017
    Assignee: Novartis AG
    Inventors: Christopher Adams, Takeru Ehara, Keith Jendza, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Nello Mainolfi, James Powers, Michael Serrano-Wu, Chun Zhang
  • 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF
    Publication number: 20160311779
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 29, 2014
    Publication date: October 27, 2016
    Applicant: NOVARTIS AG
    Inventors: Christopher ADAMS, Takeru EHARA, Keith JENDZA, Nan JI, Toshio KAWANAMI, Nello MAINOLFI, James J. POWERS, Michael SERRANO-WU, Chun ZHANG, Rajeshri Ganesh KARKI
  • SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS
    Publication number: 20160031874
    Abstract: Disclosed are substituted aminothiazoles, which can be used for, among other things, the treatment of tuberculosis, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Inventors: Deborah Hung, Michael Serrano-Wu, Sarah Grant, Tomohiko Kawate
  • Hepatitis C virus inhibitors
    Patent number: 8735398
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: May 27, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Omar D. Lopez, Denis R. St. Laurent, Jason Goodrich, Jeffrey Lee Romine, Michael Serrano-Wu, Fukang Yang, Ramesh Kakarla, Xuejie Yang, Yuping Qiu, Lawrence B. Snyder
  • Hepatitis C virus inhibitors
    Patent number: 8383094
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Makonen Belema, Van N. Nguyen, Michael Serrano-Wu, Denis R. St. Laurent, Yuping Qiu, Min Ding, Nicholas A. Meanwell, Lawrence B. Snyder
  • Hepatitis C virus inhibitors
    Patent number: 8362020
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: January 29, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Omar D. Lopez, Denis R. St. Laurent, Jason Goodrich, Jeffrey Lee Romine, Michael Serrano-Wu, Fukang Yang, Ramesh Kakarla, Xuejie Yang, Yuping Qiu, Lawrence B. Snyder
  • Inhibitors of HCV replication
    Patent number: 8143288
    Abstract: Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: March 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Serrano-Wu, Makonen Belema, Lawrence B. Snyder, Nicholas A. Meanwell, Denis R. St. Laurent, Ramesh Kakarla, Van N. Nguyen, Yuping Qiu, Xuejie Yang, John E. Leet, Min Gao, Donald R. O'Boyle, II, Julie A. Lemm, Fukang Yang
  • Hepatitis C Virus Inhibitors
    Publication number: 20110294819
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: December 21, 2010
    Publication date: December 1, 2011
    Inventors: Omar D. Lopez, Denis R. St. Laurent, Jason Goodrich, Jeffrey Lee Romine, Michael Serrano-Wu, Fukang Yang, Ramesh Kakarla, Xuejie Yang, Yuping Qiu, Lawrence B. Snyder
  • Hepatitis C virus inhibitors
    Patent number: 7906655
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: March 15, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Makonen Belema, Andrew C. Good, Jason Goodrich, Ramesh Kakarla, Guo Li, Omar D. Lopez, Van N. Nguyen, Jayne Kapur, Yuping Qiu, Jeffrey Lee Romine, Denis R. St. Laurent, Michael Serrano-Wu, Lawrence B. Snyder, Fukang Yang
  • Hepatitis C Virus Inhibitors
    Publication number: 20100080772
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 1, 2010
    Inventors: Makonen Belema, Van N. Nguyen, Michael Serrano-Wu, Denis R. St. Laurent, Yuping Qiu, Min Ding, Nicholas A. Meanwell, Lawrence B. Snyder
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20100068176
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: August 5, 2009
    Publication date: March 18, 2010
    Inventors: Makonen Belema, Andrew C. Good, Jason Goodrich, Ramesh Kakarla, Guo Li, Omar D. Lopez, Van N. Nguyen, Jayne Kapur, Yuping Qiu, Jeffrey Lee Romine, Denis R. St. Laurent, Michael Serrano-Wu, Lawrence B. Snyder, Fukang Yang
  • Iminothiazolidinones as inhibitors of HCV replication
    Patent number: 7183302
    Abstract: Compounds having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: February 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Lee Romine, Scott W. Martin, Lawrence B. Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse, Julie Lemm, Donald O'Boyle, Min Gao, Richard Colonno
  • Inhibitors of HCV replication
    Publication number: 20060276511
    Abstract: Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.
    Type: Application
    Filed: June 5, 2006
    Publication date: December 7, 2006
    Inventors: Michael Serrano-Wu, Makonen Belema, Lawrence Snyder, Nicholas Meanwell, Denis St. Laurent, Ramesh Kakarla, Van Nguyen, Yuping Qiu, Xuejie Yang, John Leet, Min Gao, Donald O'Boyle, Julie Lemm, Fukang Yang
  • Iminothiazolidinones as inhibitors of HCV replication
    Publication number: 20050096364
    Abstract: Compounds having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.
    Type: Application
    Filed: August 8, 2003
    Publication date: May 5, 2005
    Inventors: Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse, Julie Lemm, Donald O'Boyle, Min Gao, Richard Colonno
  • Combination pharmaceutical agents as inhibitors of HCV replication
    Publication number: 20050069522
    Abstract: Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound effective to inhibit the function of the HCV NS5A protein and another compound having anti-HCV activity. Compounds which can inhibit the function of the NS5A protein having the structure of formula I are described wherein R, R?, R1, R2, and R3 are as defined in the specification. The other compounds having anti-HCV activity are effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.
    Type: Application
    Filed: August 8, 2003
    Publication date: March 31, 2005
    Inventors: Richard Colonno, Julie Lemm, Donald O'Boyle, Min Gao, Jeffrey Romine, Scott Martin, Lawrence Snyder, Michael Serrano-Wu, Milind Deshpande, Darren Whitehouse
  • Thio derivatives of sordarin as antifungal agents
    Patent number: 6436930
    Abstract: The present invention relates to antifungal compounds having the structural formula: and pharmaceutically acceptable salts, solvates and prodrugs thereof. The present invention further relates to pharmaceutical compositions containing said compound, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in the treatment of a fungal infection in an animal host.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: August 20, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Serrano-Wu, Xuhua Du, Neelakantan Balasubramanian, Denis R. St. Laurent